SAGE Therapeutics (NASDAQ: SAGE) reported Q4 EPS of ($2.47), $0.10 worse than the analyst estimate of ($2.37). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $1.95 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.